Scientists are exploring an unlikely new tool in the fight against cancer: engineered bacteria that can both manufacture and deliver therapeutic drugs directly to tumors. The approach aims to address a persistent problem in oncology — the severe side effects caused by chemotherapy, which circulates throughout the body and damages healthy tissue alongside malignant cells.
When people take medication, they often experience side effects, and this is particularly true for individuals receiving chemotherapy. To minimize those effects and target tumors more directly, researchers are investigating new methods of drug delivery. Bacteria offer a distinctive advantage: in addition to carrying drugs to the right location, they can produce the drugs themselves using their own cellular machinery, effectively acting as microscopic pharmaceutical factories.
The concept involves genetically engineering microorganisms so that they home in on cancerous tissue and synthesize therapeutic agents on site. One molecule of interest is IL2, an immune signaling protein that can stimulate the body's defenses against tumors but is difficult to administer systemically due to toxicity. By programming bacteria to produce IL2 locally, researchers hope to concentrate the therapeutic effect where it is needed while sparing the rest of the body.
Scientists are also working on control mechanisms to manage the bacteria once they are inside the patient. This includes engineering the microorganisms to switch on drug production only under specific conditions, such as when they reach the tumor microenvironment, and to be safely cleared from the body after their task is complete. The research extends beyond bacteria to other microorganisms, including parasites, which are being studied for their potential to carry therapeutic payloads.
The work is part of a broader effort to develop a fleet of biological treatments against diseases such as cancer. Many of the microorganisms under investigation are more commonly known for their disease-causing capabilities, but through genetic modification they could be repurposed as allies in medicine. The field is still in its early stages, and more animal and human trials are required before genetically engineered bacteria are used routinely to deliver drugs in clinical practice.
If these trials succeed, the approach could represent a significant shift in how anticancer drugs are administered. Rather than relying solely on systemic infusions that affect the whole body, physicians might one day deploy engineered microbes that travel to the tumor and release medication precisely where it can do the most good. This strategy has the potential to improve treatment efficacy while reducing the debilitating side effects that many cancer patients endure.
The research reflects a growing interest in using living cells as therapeutic agents, a field that bridges synthetic biology, immunology, and oncology. While significant hurdles remain — including ensuring safety, stability, and predictable behavior of the engineered organisms in the human body — the potential benefits are driving sustained scientific investment. The findings were published in Nature, highlighting the mainstream scientific interest in this emerging approach to cancer therapy.